Parkwood LLC 89bio, Inc. Transaction History

Parkwood LLC

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 15, 2024	SELL	$8.13 - $13.77 $142,315 - $241,043	-17,505 Reduced 39.6%	26,701 $311,000
Q4 2023 Feb 14, 2024	BUY	$6.66 - $16.03 $108,831 - $261,946	16,341 Added 58.64%	44,206 $494,000
Q3 2023 Nov 14, 2023	BUY	$15.06 - $19.41 $65,360 - $84,239	4,340 Added 18.45%	27,865 $430,000
Q2 2023 Aug 14, 2023	BUY	$14.15 - $22.03 $332,878 - $518,255	23,525 New	23,525 $446,000

158

108M

73.6K

1.19M

Ticker ETNB
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 46,484,500
Market Cap $387M
Description
89bio, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. Its lead product candidate is pegozafermin, a glycoPEGylated analog of fibroblast growth factor 21 for the treatment of nonalcoholic steatohepatitis. The company also int...

Get notified when there are updates to the investment portfolio of Parkwood LLC, based on Form 13F filings with the SEC.

Stay updated on Parkwood LLC with notifications on news.